首页> 外文OA文献 >Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.
【2h】

Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.

机译:哈格曼因子,血浆前激肽释放酶,高分子量激肽原和血浆凝血活酶前体之间的相互作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To investigate the earliest steps of the intrinsic clotting pathway, Hageman factor (Factor XII) was exposed to Sephadex gels to which ellagic acid had been adsorbed; Hageman factor was then separated from the gels and studied in the fluid phase. Sephadex-ellagic acid-exposed Hageman factor, whether purified or in plasma, activated plasma thromboplastin antecedent, but only when high molecular weight kininogen was presnet. In the absence of plasma prekallikrein, maximal activation of plasma thromboplastin antecedent was slightly delayed in plasma, a delay not observed with similarly treated purified Hageman factor. Thus, high molecular weight kininogen was needed for expression of Hageman factor's clot-promoting properties and plasma prekallikrein played a minor role in the interaction of ellagic acid-treated Hageman factor and plasma thromboplastin antecedent.
机译:为了研究固有凝血途径的最早步骤,将Hageman因子(因子XII)暴露于已吸附鞣花酸的Sephadex凝胶中。然后从凝胶中分离出Hageman因子并在液相中进行研究。暴露于Sephadex-鞣花酸的Hageman因子,无论是纯化的还是血浆中的,均可激活血浆促凝血酶原酶的先决条件,但前提是必须使用高分子量激肽原。在不存在血浆前激肽释放酶的情况下,血浆中血浆促凝血酶原酶前体的最大激活被稍微延迟,用类似处理的纯化的Hageman因子未观察到延迟。因此,需要高分子量激肽原来表达Hageman因子的凝块促进特性,血浆前激肽释放酶在鞣花酸处理的Hageman因子与血浆凝血活酶前体的相互作用中起次要作用。

著录项

  • 作者

    Ratnoff, O D; Saito, H;

  • 作者单位
  • 年度 1979
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号